Tubulis Technologies

Private

#Oncology #Solid Tumors #Hematologic Malignancies #Antibody-Drug Conjugates (ADCs)

Tubulis is a biotechnology company developing a new generation of antibody-drug conjugates (ADCs) for the treatment of cancer. Its proprietary platforms — Tub-tag, P5 conjugation, and Topoisomerase-I inhibitor payloads — enable the design of highly stable, targeted ADCs with improved therapeutic index. In May 2026, Gilead Sciences completed the acquisition of Tubulis for up to $5 billion ($3.15B cash upfront + $1.85B milestones).

Company Info

Sector: Biotechnology / Oncology / ADC

Headquarters: Planegg-Martinsried, Germany

Founded: 2019

Website: tubulis.com/

Funding Round: Series B2 (pre-acquisition)

Total Funding: ~$200M (lifetime)

Funding & Investor Relations

Notable Investors

Andera Partners
LSP (Life Sciences Partners)
Evotec
BioGeneration Ventures
Coparion
Seventure Partners
High-Tech Gründerfonds

IPO Outlook / Plans

Acquisition by Gilead Sciences completed in May 2026 for up to $5 billion ($3.15B upfront cash + $1.85B milestones).

Upcoming Milestones & Key Dates

Mid-2026

M&A

Integration of Tubulis into Gilead's oncology research group as the Tubulis ADC Innovation Center

Late 2026

Clinical Trial

Clinical updates from the ongoing NAPISTAR 1-01 trial of TUB-040

Clinical Development Pipeline

TUB-040

Target: NaPi2b-targeted ADC (Topoisomerase-I inhibitor payload)

Platinum-Resistant Ovarian Cancer and other solid tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

TUB-030

Target: 5T4-targeted ADC (Topoisomerase-I inhibitor payload)

Advanced Solid Tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Dr. Dominik Schumacher

Chief Executive Officer and Co-Founder

Dr. Jonas Helma-Smets

Chief Scientific Officer and Co-Founder

Dr. Markus Wetzel

Chief Operating Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →